Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2024年5月30日 - 8:00PM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers, today announced that Zentalis
management is scheduled to participate in a fireside chat at the
upcoming Jefferies Global Healthcare Conference on June 5, 2024, at
4:00 p.m. ET.
Access to a live webcast of this event, as well as
an archived recording, will be available under the “Events &
Presentations” tab on the Investors & Media section of the
Company’s website.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers. The Company’s lead product
candidate, azenosertib (ZN-c3), is a potentially first-in-class and
best-in-class WEE1 inhibitor for advanced solid tumors and
hematologic malignancies. Azenosertib is being evaluated as a
monotherapy and in combination across multiple clinical trials and
has broad franchise potential. In clinical trials, azenosertib has
been well tolerated and has demonstrated anti-tumor activity as a
single agent across multiple tumor types and in combination with
several chemotherapy backbones. As part of its azenosertib clinical
development program, the Company is exploring enrichment strategies
targeting tumors of high genomic instability, such as Cyclin E1
positive tumors, homologous recombination deficient tumors and
tumors with oncogenic driver mutations. The Company is also
leveraging its extensive experience and capabilities across cancer
biology and medicinal chemistry to advance its research on protein
degraders. Zentalis has operations in both New York and San
Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on X/Twitter at @ZentalisP and on LinkedIn
at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis
and/or its affiliates. All website addresses and other links in
this press release are for information only and are not intended to
be an active link or to incorporate any website or other
information into this press release.
Contact:Elizabeth Pingpank
Hickinehickin@zentalis.com860.463.0469
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
過去 株価チャート
から 8 2024 まで 9 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
過去 株価チャート
から 9 2023 まで 9 2024